紫元元(08223.HK)中期纯利升22.99%至741.6万元
格隆汇8月9日丨紫元元(08223.HK)公布,截至2019年6月30日止6个月,收益增加12.85%至3288万元人民币(单位下同);公司拥有人应占溢利增加22.99%至741.6万元;每股基本盈利2分;不派息。
于期内,来自印刷行业的收益仍为本集团收益的最大贡献因素。来自印刷行业的收益增加主要归因于中国印刷设备需求增长及本集团努力取得该行业的新客户。与此同时,收益增加亦归因于集团自2018年10月起开始营运医疗器械行业。
此外,公司拥有人应占溢利及全面收入总额增加,主要是由于较2018年同期收益增加,以及上市开支减少,其抵销员工成本及其他经营开支之增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.